Boston Heart Lab Corp. has pulled in a funding round worth $10 million, according to a regulatory filing. The Framingham-based provider of cardiac diagnostic tests and disease management information, develops diagnostic information for assessing cardiac health and to make meaningful treatment decisions for patients.

Individuals named in the filing include CEO Susan Hertzberg, chief medical officer Ernst Schaefer, chief scientific officer Bela Asztalos and chairman of the board Peter Parker.

The company launched in 2007 and was initially funded in part by the five founders of the company to the tune of $900,000. A second fundraise, worth $2 million, included eight angel investment groups.

Boston Heart Lab’s lead product is a panel of 30 tests, five of which are proprietary, to diagnose heart disease or the risk of heart disease. Results can guide care for each individual patient by determining which type of drugs or other therapy might be most effective.

Blood is taken at a doctor’s office or hospital, as for a simple cholesterol test, and then the sample is sent to Boston Heart Lab for analysis.

The combined number of Americans who either have heart disease or are at risk to develop it is estimated to be as many as 60 million, according to Wolfgang Daum, one of the company’s founders.